Anatoli Malyguine

Dr. Anatoli Malyguine


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Expert Review of Vaccines
Verified
Journal Article
Closed access
LZLiubov Zaritskaya
Liubov Zaritskaya
Michael ShurinMichael Shurin
Michael Shurin
TSThomas J Sayers
Thomas J Sayers
AMAnatoli Malyguine
Anatoli Malyguine
(2010). New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Review of Vaccines: Vol. 9, No. 6, pp. 601-616.

10 May 2012 in Cells
Verified
Journal Article
Open access
PDF file
AMAnatoli Malyguine
Anatoli Malyguine
SSSusan Strobl
Susan Strobl
KDKimberly Dunham
Kimberly Dunham
Michael ShurinMichael Shurin
Michael Shurin
TSThomas Sayers
Thomas Sayers
The profiling and monitoring of immune responses are key elements in the evaluation of the efficacy and development of new biotherapies, and a number of assays have been introduced for analyzing various immune parameters before, during, and after immunotherapy. The choice of immune assays for a given clinical trial depends on the known or suggested immunomodulating mechanisms associated with the tested therapeutic modality. Cell-mediated cytotoxicity represents a key mechanism in the immune response to various pathogens and tumors. Therefore, the selection of monitoring methods for the appropriate assessment of cell-mediated cytotoxicity is thought to be crucial. Assays that can detect both cytotoxic T lymphocytes (CTL) frequency and function, such as the IFN-γ enzyme-linked immunospot assay (ELISPOT) have gained increasing popularity for monitoring clinical trials and in basic research. Results from various clinical trials, including peptide and whole tumor cell vaccination and cytokine treatment, have shown the suitability of the IFN-γ ELISPOT assay for monitoring T cell responses. However, the Granzyme B ELISPOT assay and Perforin ELISPOT assay may represent a more direct analysis of cell-mediated cytotoxicity as compared to the IFN-γ ELISPOT, since Granzyme B and perforin are the key mediators of target cell death via the granule-mediated pathway. In this review we analyze our own data and the data reported by others with regard to the application of various modifications of ELISPOT assays for monitoring CTL activity in clinical vaccine trials.

23 December 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
LBLisa H Butterfield
Lisa H Butterfield
MDMary Lenora Disis
Mary Lenora Disis
BFBernard A Fox
Bernard A Fox
PLPeter P. Lee
Peter P. Lee
SKSamir N Khleif
Samir N Khleif
FMFrancesco Marincola
Francesco Marincola
The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.

12 November 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
AMAnatoli Malyguine
Anatoli Malyguine
SSSusan L. Strobl
Susan L. Strobl
Michael ShurinMichael Shurin
Michael Shurin

19 October 2010 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
Michael ShurinMichael Shurin
Michael Shurin
MGMelissa Gregory
Melissa Gregory
JMJohn C Morris
John C Morris
AMAnatoli Malyguine
Anatoli Malyguine
Importance of the field: Dendritic cells (DC) are powerful antigen-presenting cells that induce and maintain primary cytotoxic T lymphocyte (CTL) responses directed against tumor antigens. Consequently, there has been much interest in their application as antitumor vaccines. Areas covered in this review: A large number of DC-based vaccine trials targeting a variety of cancers have been conducted; however, the rate of reported clinically significant responses remains low. Modification of DC to express tumor antigens or immunostimulatory molecules through the transfer of genes or mRNA transfection offers a logical alternative with potential advantages over peptide- or protein antigen-loaded DC. In this article, we review the current results and future prospects for genetically modified DC vaccines for the treatment of cancer. What the reader will gain: Genetically-modified dendritic cell-based vaccines represent a powerful tool for cancer therapy. Numerous preclinical and clinical studies have demonstrated the potential of dendritic cell vaccines alone or in combination with other therapeutic modalities. Take home message: Genetically modified DC-based anti-cancer vaccination holds promise, perhaps being best employed in the adjuvant setting with minimal residual disease after primary therapy, or in combination with other antitumor or immune-enhancing therapies.

29 May 2012 in Journal of Immunotoxicology
Verified
Journal Article
Closed access
AMAnatoli Malyguine
Anatoli Malyguine
VUVictor Umansky
Victor Umansky
BKBeatrix Kotlan
Beatrix Kotlan
NANatalia Aptsiauri
Natalia Aptsiauri
Michael ShurinMichael Shurin
Michael Shurin
The immune system is a critical element involved in the control of tumor development and progression. While professionals have learned how to manipulate the immune system to generate tumor-specific immune responses, cancer immunotherapy has not yet delivered substantial clinical benefits. It has become increasingly clear that tumor-induced abnormalities in the immune system not only hamper tumor immunosurveillance, but also limit the efficacy of cancer immunotherapy. Meanwhile, the results of recent studies allow the belief that one is on the edge of a real breakthrough in this promising direction in cancer therapy. The 2nd International Conference ‘Cancer Immunotherapy and Immunomonitoring (CITIM)’ was the second meeting in Eastern Europe to specifically focus on the issue of immune regulation in the tumor environment, cancer immunotherapy, and immunomonitoring of immunotherapeutic clinical trials. This CITIM Conference held in Budapest, Hungary, was comprised from 12 plenary sessions, Best Abstract Award session, Poster session, and four Keynote lectures. Outstanding presentations and numerous productive discussions summarized the current place of the field and opened new directions for improving monitoring and therapy for patients with cancer.